Pharmacia Trelstar LA Fourth LHRH Entrant In Prostate Cancer Arsenal
This article was originally published in Pharmaceutical Approvals Monthly
Pharmacia’s prostate cancer therapy Trelstar LA will enter the U.S. market as the fourth luteinizing hormone-releasing hormone (LHRH) analogue approved for treatment of the disease. The three-month, 11.5 mg formulation of triptorelin pamoate cleared FDA June 29 for the "palliative treatment of advanced prostate cancer."
You may also be interested in...
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class